Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment

Open access

Abstract

PD-1 (Programmed Cell Death Protein-1) and PD-L1 (Programmed Cell Death Ligand-1) play a crucial role in regulating the immune system and preventing autoimmunity. Cancer cells can manipulate this system, allowing them to escape immune detection and promote tumor growth. Therapies targeting the PD-1/PD-L1 pathway have transformed cancer treatment and have demonstrated significant effectiveness against various cancer types. This study delves into the structure and signaling dynamics of PD-1 and its ligands PD-L1/PD-L2, the diverse PD-1/PD-L1 inhibitors and their efficacy, and the resistance observed in some patients. Furthermore, this study explored the challenges associated with the PD-1/PD-L1 inhibitor treatment approach. Recent advancements in the combination of immunotherapy with chemotherapy, radiation, and surgical procedures to enhance patient outcomes have also been highlighted. Overall, this study offers an in-depth overview of the significance of PD-1/PD-L1 in cancer immunotherapy and its future implications in oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1296341

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 3D visualization of the crystal structure of PD-1 was performed using the PDB code 3RRQ. The various colors delineate distinct protein regions and conformations.
Figure 1 3D visualization of the crystal structure of PD-1 was performed using the PDB code 3RRQ. The various colors delineate distinct protein regions and conformations.CC BY · PubMed Central
Figure 2 Crystal structures of two significant programmed cell death ligands, (A) PD-L1 (PDB:4Z18) and (B) PD-L2 (PDB:3BOV).
Figure 2 Crystal structures of two significant programmed cell death ligands, (A) PD-L1 (PDB:4Z18) and (B) PD-L2 (PDB:3BOV).CC BY · PubMed Central
Figure 3 3D visualization of the crystal structure of the PD-1–PD-L1 complex. This image offers a detailed look at the structural alignment of the complex, highlighting that (A) represents PD-L1 chain and (B) represents PD-1 chain. The associated Protein Data Bank (PDB) reference for this structure is 4ZQK. This figure aids in the understanding of the intricate molecular interactions and conformation of the PD-1–PD-L1 interaction.
Figure 3 3D visualization of the crystal structure of the PD-1–PD-L1 complex. This image offers a detailed look at the structural alignment of the complex, highlighting that (A) represents PD-L1 chain and (B) represents PD-1 chain. The associated Protein Data Bank (PDB) reference for this structure is 4ZQK. This figure aids in the understanding of the intricate molecular interactions and conformation of the PD-1–PD-L1 interaction.CC BY · PubMed Central
Figure 4 Overview of the impact of PD-1–PD-L1 interaction on T-cells. When PD-L1 binds to PD-1, it induces SHP-2, diminishing ZAP70 phosphorylation and dampening the RAS-MEK-ERK and PI3K-Akt pathways. This results in suppressed T-cell activity, including proliferation, activation, cytokine production, and longevity.
Figure 4 Overview of the impact of PD-1–PD-L1 interaction on T-cells. When PD-L1 binds to PD-1, it induces SHP-2, diminishing ZAP70 phosphorylation and dampening the RAS-MEK-ERK and PI3K-Akt pathways. This results in suppressed T-cell activity, including proliferation, activation, cytokine production, and longevity.CC BY · PubMed Central
Figure 5 Timeline of FDA and NMPA-approved PD-1/PD-L1 immune checkpoint inhibitors from 2014 to 2021, detailing the progression of approvals over the years.
Figure 5 Timeline of FDA and NMPA-approved PD-1/PD-L1 immune checkpoint inhibitors from 2014 to 2021, detailing the progression of approvals over the years.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 145 references

Research works printed but not linked: 2

  1. 2023, Worldwide cancer incidence statistics, Cancer Res UK
  2. Preparation, storage and administration of KEYTRUDA® (pembrolizumab), IHCP

Cited by

See all 216

Metadata

Authors
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A.
Affiliations
  • Jamia Hamdard (IN)
  • Qassim University (SA)
  • Tampere University (FI)
Corresponding author
  • Qureshi, Kamal A.
  • Farooqi, Humaira
  • Aspatwar, Ashok
Venue
Frontiers in Immunology
Published
2023-12-01
Volume
14
Pages
1296341-1296341
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4389233067
Cited by
216
References
145
Citations by year
2026: 61 · 2025: 108 · 2024: 47
FWCI
6.98
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by)
Funders
Tampereen Yliopisto
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
PD-1, PD-L1, PD-L2, immune checkpoint, cancer immunotherapy, immune evasion, PD-1/PD-L1 inhibitors, treatment resistance, combination therapy, tumor immune microenvironment
MeSH terms
Antibodies, Monoclonal, Humans, Immunotherapy, Neoplasms, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. https://app.cochat.ai/papers/10.3389/fimmu.2023.1296341
The paper
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023). PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1296341

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.